INTEG-B Integrum AB (publ)
Integrum AB (publ) researches, develops, and sells various systems for bone-anchored prostheses. The company provides prostheses for the Rehabilitation of Amputees (OPRA) implant systems, a bone-anchored prostheses system based on osseointegration, where the prostheses are directly attached to the bone, avoiding the use of socket. The OPRA implant system offers protection to the patient by avoiding bone fractures from accidental loads. It also provides Neuromotus, a technology that is used for therapy to reduce phantom limb pain after an amputation. It sells its implant systems to hospitals, clinics, and orthopedists worldwide. The company was incorporated in 1990 and is headquartered in Mölndal, Sweden.…
Industry Peers
Medical DevicesKey Statistics
About Integrum (STO: INTEG-B)
›
Integrum (STO: INTEG-B) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 33 employees.
The shares were at 8.200 SEK on 19 November 2026, down 2.8% over 52 weeks. Its 52-week range is 6.400 SEK to 11.94 SEK: the price is 31.3% below the high and 28.1% above the low.
Its market capitalisation is 218.68M SEK.
Integrum reports return on equity of -26.9%, an operating margin of -37.9% and revenue up 27.2% year over year.
It holds more cash than debt, a net cash position of 12.27M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. The next earnings report is expected on 20 November 2026.